Home      Login

Abstract: 

A large-scale recall of generic atorvastatin—one of the most widely prescribed drugs in the United States—highlights a troubling vulnerability in the nation’s pharmaceutical supply chain. This article explains how defective tablets that fail to dissolve properly may silently increase patients’ risk of heart attack and stroke, even when taken as directed. Beyond the immediate recall, it situates the problem within a broader pattern of manufacturing lapses at overseas facilities and gaps in FDA inspection capacity. For clinicians, policymakers, and patients alike, the piece raises urgent questions about drug quality, regulatory oversight, and the hidden risks embedded in routine treatment.

Keywords: Atorvastatin Recall; Drug Manufacturing Quality; FDA Oversight; Generic Drugs; Pharmaceutical Supply Chain

Affiliations:  1: University of Connecticut School of Pharmacy.